<DOC>
	<DOCNO>NCT01796821</DOCNO>
	<brief_summary>To evaluate efficacy SR-T100 gel observe total clearance rate treat baseline EGW ( ) treat area .</brief_summary>
	<brief_title>Efficacy Safety Profiles SR-T100 Gel External Genital Warts/Condyloma Acuminate ( EGWs )</brief_title>
	<detailed_description>A double-blind , randomize , vehicle-controlled , parallel-group , dose-ranging study evaluate efficacy safety SR-T100 gel patient EGW ( ) . The primary efficacy endpoint define proportion patient whose baseline EGW ( ) treat area achieve total clearance . The efficacy SR-T100 gel prevention new EGW ( ) occurrence evaluate . Distinct exist medication EGWs , SR-T100 gel possess characteristic high safety low LSR causality . SR-T100 gel administer EGW lesion ( ) clearance surround clinical normal skin prevention new EGW ( ) occurrence .</detailed_description>
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>1 . Male female ; age ≥ 20 year old . 2 . Patients accept enter study sign write informed consent . 3 . Each patient 1 10 clinically diagnose EGW ( ) . If patient 1 genital wart , diameter genital wart must less 5 mm . 4 . Female patient lesion ( ) labium majora , labia minora , clitoris and/or groin . 5 . Male patient lesion ( ) glans , shaft and/or foreskin . 6 . Each patient least 1 histologically proved EGW . 7 . Patients agree apply study medication `` clinical diagnosed lesion ( ) '' occlusive dressing ( ) daily least 20 hour per day `` clinical normal skin treat area '' thrice daily without occlusive dressing . 8 . Patients allow diagram mapping photography genital wart . And patient agree use data part study data package . 9 . Patients good general health condition ( performance status ≤ 2 Eastern Cooperative Oncology Group ( ECOG ) ) . 10 . Female patient childbearing potential must take reliable contraception method ( ) participation study . 11 . Patients must agree use effective boundary barrier birth control reinfection EGW 1 . Patients perianal wart . 2 . Male patient wart scrotum perineum . 3 . Patients genital infection . 4 . Patients internal genital wart ( urethral , intravaginal , cervical , rectal , intraanal genital wart ) . 5 . Patients active systemic infection . 6 . Patients genital disease may confound evaluation treatment genital wart . 7 . Patients immunocompromised medical condition . 8 . Patients receive investigational drug prior 30 day randomization visit . 9 . Patients cancer cancer history within 5 year randomization visit . 10 . Patients ongoing human papilloma virus ( HPV ) infection genital area . 11 . Patients human immunodeficiency virus ( HIV ) , venereal disease research laboratory ( VDRL ) , treponema pallidum particle agglutination assay ( TPHA ) positive result . 12 . Female patient highgrade pathology Papanicolaou smear test base Bethesda system . 13 . Female patient pregnant lactate . 14 . Patients history allergy sensitivity Solanum undatum plant extract , SM , SRT100 gel excipients include carbomer , propylene glycol , triethanolamine . 15 . Patients prohibited premedication procedure show : 1 . Physical modality , laser ablation , electrocautery cryotherapy , genital wart treatment treat area within 4 week prior randomization visit . 2 . Topical administered medication genital wart treatment , polyphenon E , podophyllotoxin , imiquimod , 5fluorouracil ( 5FU ) , within 12 week prior randomization . 3 . Medications cytotoxic , immunomodulator ( inhaled topical steroid anogenital area prohibit ) , systematic antiviral agent 4 week prior randomization visit .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Condyloma acuminata</keyword>
	<keyword>Genital wart</keyword>
	<keyword>Condylomata acuminata</keyword>
	<keyword>Venereal wart</keyword>
</DOC>